Luspatercept (Reblozyl; Bristol Myers Squibb) can reduce the need for red blood cell transfusions. The study, published in HemaSphere, found the therapy had similar efficacy in real-world usage as it did in its pivotal clinical trials. Severe anemia and transfusion dependency have both been linked with a shorter overall survival.